Erb Takes Root As Sunshine Heart CEO
This article was originally published in Clinica
Heart failure device developer Sunshine Heart Inc. has appointed John Erb CEO, effective March 2. Erb had been filling in as interim CEO after the departure of former chief David Rosa in December. Rosa left amid the company’s struggles with the US pivotal trial for its C-Pulse system. Erb, who has more than 40 years of experience in medical device leadership and financial posts, has served as the director of Sunshine Heart since September 2012 and was named chairman in October 2012. He is a founder of NuAx Inc. – formerly Cardia Access Inc. – and from 2001 through 2006 he served as CEO of CHF Solutions Inc., which was acquired by Gambro Inc.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.